Mendes Jorge M et al., 2019-10-10: Burkina Faso randomized trial in children 6-59 months: methylene blue 15 mg/kg/day for 3 days with artesunate-amodiaquine was not non-inferior to primaquine on haemoglobin recovery at day 7, though gametocyte carriage fell faster.
MB-AS-AQ could not be shown to be non-inferior to PQ-AS-AQ (mean Hb difference between treatment groups on day 7 was -0.352, 95% CI -0.832-0.128, p = 0.0767)
Mendes Jorge M et al., 2019-10-10: Burkina Faso randomized trial in children 6-59 months: methylene blue 15 mg/kg/day for 3 days with artesunate-amodiaquine was not non-inferior to primaquine on haemoglobin recovery at day 7, though gametocyte carriage fell faster. C10 (mixed result). Study type: randomized, non-inferiority trial, N=100 (50 per arm), children 6-59 months with uncomplicated falciparum malaria, Burkina Faso; Heidelberg Institute of Global Health (Germany) with Burkinabe partners. Dose: methylene blue 15 mg/kg/day for 3 days vs primaquine 0.25 mg/kg at day 2, both on artesunate-amodiaquine. Day 7 mean Hb difference -0.352 g/dL (95% CI -0.832 to 0.128; p=0.0767) so non-inferiority was not shown; vomiting more frequent with methylene blue (20/50 vs 7/50, p=0.003); asexual parasite clearance and gametocyte reduction favoured methylene blue. Trial registration NCT02851108. Funder not stated in the abstract. PARTLY: benefit on transmission-stage endpoints, failure on the haematological primary endpoint. Also filed as MTL-008, MTP-28 (claims C1, C10, C4). Study type: randomized trial.
